Premium
Reply to Letter ‘Morning dosing for dolutegravir‐related insomnia and sleep disorders’ by Capetti et al .
Author(s) -
Hoffmann C,
Welz T,
Sabranski M,
Kolb M,
Wolf E,
Stellbrink HJ,
Wyen C
Publication year - 2018
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12539
Subject(s) - medicine , irritability , dosing , discontinuation , adverse effect , insomnia , quetiapine , dolutegravir , psychiatry , anxiety , raltegravir , depression (economics) , akathisia , tolerability , pediatrics , antipsychotic , schizophrenia (object oriented programming) , family medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , economics , macroeconomics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom